Search results
Showing 211 to 224 of 224 results for mental health learning disabilities
Interim methods guide for developing good practice guidance (PMG15)
This interim methods guide is based on the general principles and methods included in other methods guides for developing NICE guidance
One-piece closed bags for colostomies: late-stage assessment (HTG754)
Late stage assessment (LSA) guidance on one-piece closed bags for colostomies
View recommendations for HTG754Show all sections
Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment (HTG751)
Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers.
View recommendations for HTG751Show all sections
This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used
Neonatal infection: antibiotics for prevention and treatment (NG195)
This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.
Slide sheets for moving or repositioning a person: late-stage assessment (HTG745)
Late-stage assessment (LSA) guidance on slide sheets for moving or repositioning a person.
Methods for the development of NICE public health guidance (third edition) (PMG4)
This manual describes the methods used by the Centre for Public Health Excellence (CPHE) in NICE to develop and update public health guidance
This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.
This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes
Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)
Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over.
NICE technology appraisal and highly specialised technologies guidance: the manual (PMG36)
This guide describes the methods and processes, including expected timescales, that NICE follows when carrying out health technology evaluations. The methods and processes are designed to produce robust guidance for the NHS in an open, transparent and timely way, with appropriate contribution from stakeholders. Organisations invited to contribute to health technology evaluation development should read this manual in conjunction with the NICE health technology evaluation topic selection: the manual. All documents are available on the NICE website
This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women and pregnant people to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.
View recommendations for NG235Show all sections
Sections for NG235
- Overview
- Recommendations
- Recommendations for research
- Rationale and impact
- Context
- Appendix A: Adverse outcomes for different places of birth
- Appendix B: Outcomes for different places of birth – by BMI at booking
- Appendix C: Outcomes for intravenous remifentanil patient-controlled analgesia (PCA) compared with intramuscular pethidine